Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MAIA Biotechnology, Inc.

< Previous 1 2 Next >
MAIA Biotechnology Announces $2.44 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present at the BIO International Convention 2024
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces $1.00 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces $1.33 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces $4 Million Registered Direct Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.